Jiangxi Institute of Biological Products Inc (HKSE:06915) Share Price

Company Profile

Business description
Jiangxi Institute of Biological Products Inc is principally engaged in the business of research and development, and production and sale of human tetanus antitoxin. It operates as the provider and exporter of Human TAT in China and an antiserum platform company. Its products include biological products containing immunoglobulins or immunoglobulin F(ab')2 fragments, which are used in medical applications such as tetanus, snakebite envenoming, and rabies treatment. The majority of the company's revenue is derived from the sale of Human Tetanus Antitoxin in the Chinese mainland.
Contact
No. 198 Huoju Avenue
Jinggangshan Economic and Technological Development Zone
Jiangxi Province
Ji’an
CHN
T: +86 75533209772
https://www.jxswzp.cn
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
349

Recommended

Shares have fallen over 40% this year but revenue is still growing quickly.

Roy Van Keulen | 10 November 2026

Store closures could hit landlords.

Yingqi Tan, CFA | 09 November 2026

Short term pain, long term potential.

Esther Holloway | 09 November 2026

Index	Last price	Change	% Change
All Ordinaries	9,291.30	23.50	0.25%
CAC 40	8,312.33	33.74	0.41%
DAX 40	26,591.31	243.86	0.93%
Dow JONES (US)	52,176.09	55.80	-0.11%
FTSE 100	10,799.04	47.45	0.44%
HKSE	24,315.92	241.12	-0.98%
NASDAQ	25,458.18	392.31	1.57%
Nikkei 225	61,248.59	789.01	1.31%
NZX 50 Index	14,179.86	12.45	0.09%
S&P 500	7,597.64	76.71	1.02%
S&P/ASX 200	9,153.20	24.20	0.27%
SSE Composite Index	3,680.64	16.92	0.46%